Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

BIOMARKER:

PD-1 expression

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Entrez ID:

Related biomarkers:

‹

›

PD-1 expression	Bladder Cancer	PD-1 expression	Bladder Cancer	cisplatin Sensitive: C3 – Early Trials cisplatin Sensitive : C3	cisplatin Sensitive: C3 – Early Trials cisplatin Sensitive : C3
PD-1 expression	Urothelial Cancer	PD-1 expression	Urothelial Cancer	pembrolizumab + GSK3359609 Sensitive: C3 – Early Trials pembrolizumab + GSK3359609 Sensitive : C3	pembrolizumab + GSK3359609 Sensitive: C3 – Early Trials pembrolizumab + GSK3359609 Sensitive : C3
PD-1 expression	Renal Cell Carcinoma	PD-1 expression	Renal Cell Carcinoma	nivolumab Sensitive: C3 – Early Trials nivolumab Sensitive : C3	nivolumab Sensitive: C3 – Early Trials nivolumab Sensitive : C3
PD-1 expression	Renal Cell Carcinoma	PD-1 expression	Renal Cell Carcinoma	toripalimab Sensitive: C3 – Early Trials toripalimab Sensitive : C3	toripalimab Sensitive: C3 – Early Trials toripalimab Sensitive : C3
PD-1 expression	Merkel Cell Carcinoma	PD-1 expression	Merkel Cell Carcinoma	Immunotherapy Sensitive: C3 – Early Trials Immunotherapy Sensitive : C3	Immunotherapy Sensitive: C3 – Early Trials Immunotherapy Sensitive : C3
PD-1 expression	Sarcoma	PD-1 expression	Sarcoma	nivolumab + NKTR-214 Sensitive: C3 – Early Trials nivolumab + NKTR-214 Sensitive : C3	nivolumab + NKTR-214 Sensitive: C3 – Early Trials nivolumab + NKTR-214 Sensitive : C3
PD-1 expression	Cutaneous Melanoma	PD-1 expression	Cutaneous Melanoma	Immunotherapy Sensitive: C3 – Early Trials Immunotherapy Sensitive : C3	Immunotherapy Sensitive: C3 – Early Trials Immunotherapy Sensitive : C3
PD-1 expression	Esophageal Squamous Cell Carcinoma	PD-1 expression	Esophageal Squamous Cell Carcinoma	nivolumab Sensitive: C3 – Early Trials nivolumab Sensitive : C3	nivolumab Sensitive: C3 – Early Trials nivolumab Sensitive : C3
PD-1 expression	Gastroesophageal Junction Adenocarcinoma	PD-1 expression	Gastroesophageal Junction Adenocarcinoma	atezolizumab Sensitive: C3 – Early Trials atezolizumab Sensitive : C3	atezolizumab Sensitive: C3 – Early Trials atezolizumab Sensitive : C3
PD-1 expression	Gastric Cancer	PD-1 expression	Gastric Cancer	atezolizumab Sensitive: C3 – Early Trials atezolizumab Sensitive : C3	atezolizumab Sensitive: C3 – Early Trials atezolizumab Sensitive : C3
PD-1 expression	Gastroesophageal Junction Adenocarcinoma	PD-1 expression	Gastroesophageal Junction Adenocarcinoma	nivolumab + ipilimumab Sensitive: C3 – Early Trials nivolumab + ipilimumab Sensitive : C3	nivolumab + ipilimumab Sensitive: C3 – Early Trials nivolumab + ipilimumab Sensitive : C3
PD-1 expression	Melanoma	PD-1 expression	Melanoma	toripalimab Sensitive: D – Preclinical toripalimab Sensitive : D	toripalimab Sensitive: D – Preclinical toripalimab Sensitive : D